tetrindole | 170964-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: tetrindole
• 英文别名: 8-Cyclohexyl-2,3,3a,4,5,6-hexahydro-1H-pyrazino[3,2,1-jk]carbazole；12-cyclohexyl-1,4-diazatetracyclo[7.6.1.05,16.010,15]hexadeca-9(16),10(15),11,13-tetraene
• CAS: 170964-67-7
• 化学式: C₂₀H₂₆N₂
• mdl: MFCD00409220
• 分子量: 294.44
• InChiKey: AUXCHYJDVJZEPG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  22
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  17
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  tetrindole 在 potassium permanganate 、 四丁基溴化铵 作用下， 以 苯 为溶剂， 反应 3.0h， 以98%的产率得到8-Cyclohexyl-2,4,5,6-tetrahydro-1H-pyrazino<3,2,1-jk>carbazole
  参考文献：
  名称：

  (S) - (+) - 和 (R) - (-) - MAO-A 抑制剂 Tetrindole Hydrochloride 的异构体的拆分、EPC 合成、绝对立体化学和药理学

  摘要：

  (RS)-tetrindole (3) 的拆分和亚胺 7 的对映选择性还原产生 (S) - (+) - (4) 和 (R) - (-) - tetrindole (5)。4 的绝对立体化学是通过相应的 Mosher 酰胺 6 的 X 射线分析建立的。 从体外和体内数据（MAO 抑制、大鼠脑中单胺及其各自代谢物的水平），4 被确定为 eutomer .

  DOI：

  10.1002/ardp.19953280710

文献信息

• HYDROCHLORIDE 2,3,3a,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-j,k)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT
  申请人：VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INST. IMENI SERGO ORDZHONIKIDZE (VNIKHFI)

  公开号：EP0457908A1

  公开（公告）日：1991-11-27

  Hydrochloride 2,3,3a,4,5,6-hexahydro-8-cyclohexyl-1H-pyrazino (3,2,1-j,k)carbazol has formula (I). A method of obtaining the claimed composition consists in that 6-cyclohexyl-3,4-dihydrocarbazol-1(2H) is alkylated by hydrochloride β-(N,N-dibenzylamino) ethylchloride in a two-phase system: an aromatic hydrocarbon-34-40 %-aqueous solution of alkali in the presence of an interphase transfer catalyst at a temperature of 85-110 °C with subsequent hydrogenation of the resulting 6-cyclohexyl-9β-(N,N-dibenzylamino) ethyl-3,4-dihydrocarbazol-1(2H) over palladium catalyst on a carrier in the medium of a higher aliphatic alcohol at a temperature of 50-70 °C and under a pressure of 1 to 30 atm with subsequent transfer of the obtained 2,3,3a,4,5,6-hexahydro-8-cyclohexyl-1H-pyrazino (3,2,1-j,k)carbazol into hydrochloride and extraction of the latter. The claimed composition has an antidepressive action and is an active substance of a pharmaceutical preparation with antidepressive action.

  盐酸2,3,3a,4,5,6-六氢-8-环己基-1H-吡唑(3,2,1-j,k)咔唑的化学式为(I)。获得所述化合物的方法包括以下步骤：在芳香烃-34-40%碱性水溶液的两相体系中，加入相转移催化剂，将6-环己基-3,4-二氢咔唑-1(2H)与盐酸β-(N,N-二苯基氨基)乙基氯乙烷烷基化，反应温度为85-110°C，然后在高级脂肪醇介质中，于50-70°C、1-30大气压下，将所得的6-环己基-9β-(N,N-二苯基氨基)乙基-3,4-二氢咔唑-1(2H)在钯催化剂载体上进行氢化，随后将得到的2,3,3a,4,5,6-六氢-8-环己基-1H-吡唑(3,2,1-j,k)咔唑转化为盐酸盐并提取。所述化合物具有抗抑郁作用，是一种抗抑郁药物的活性成分。
• Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
  申请人：Kõster Hubert

  公开号：US20100248264A1

  公开（公告）日：2010-09-30

  Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Automated systems for performing the methods also are provided.

  提供了捕获化合物及其集合以及使用这些化合物进行生物分子分析的方法。特别地，提供了用于分析复杂蛋白质混合物（如蛋白质组）的集合、化合物和方法。这些化合物是多功能试剂，可用于分离和分离复杂的蛋白质混合物。还提供了执行这些方法的自动化系统。
• Compositions and methods for treating mitochondrial diseases
  申请人：BIOVISTA, INC.

  公开号：US10172854B2

  公开（公告）日：2019-01-08

  The invention described herein relates to methods for treating mitochondrial diseases. In particular, the invention relates to methods for treating mitochondrial diseases by administering therapeutically effective amounts of one or more tetracyclic pyrazinoindoles, and/or pharmaceutically acceptable salts thereof.

  本文所述的发明涉及治疗线粒体疾病的方法。特别是，本发明涉及通过施用治疗有效量的一种或多种四环吡嗪吲哚和/或其药学上可接受的盐来治疗线粒体疾病的方法。
• Compositions and methods for diagnosis and treatment of prostate cancer
  申请人：Mounir Zineb

  公开号：US10479997B2

  公开（公告）日：2019-11-19

  The invention provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating subjects having TMPRSS2:ERG positive prostate cancer, which we show is amenable to therapeutic treatment with a PRMT5 inhibitor. Kits, methods of screening for candidate PRMT5 inhibitors, and associated methods of treatment are also provided.

  本发明提供了用于治疗TMPRSS2:ERG阳性前列腺癌受试者的新型个性化疗法、试剂盒、可传输的信息形式和方法。我们还提供了试剂盒、筛选候选 PRMT5 抑制剂的方法以及相关的治疗方法。
• METHODS FOR TREATING MULTIPLE SCLEROSIS USING TETRACYCLIC PYRAZINOINDOLES
  申请人：Biovista, Inc.

  公开号：EP2375900A1

  公开（公告）日：2011-10-19